Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00279110 · ClinicalTrials.gov registry record · Phase 2

Directly Administered HIV Therapy in Methadone Clinics

A Phase 2 study of HIV Infections and Heroin Dependence, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 2
Development phase
107
Enrollment target
5
Study locations

NCT00279110 is a Phase 2 study of HIV Infections and Heroin Dependence that has completed, run by Johns Hopkins University. The registered enrollment target is 107 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00279110, a Phase 2 study of HIV Infections and Heroin Dependence, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 2
Development phase
107 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to determine whether providing directly administered antiretroviral therapy to HIV-infected who receive methadone therapy leads to better treatment outcomes than if they take HIV medications on their own.

Interventions

  • BEHAVIORAL Directly administered antiretroviral therapy (DAART)

Study Locations (5)

Maryland

  • Baltimore VA Drug Dependency Program - Baltimore
  • Program for Alcohol and Other Drug Dependencies - Baltimore
  • Man Alive, Inc. - Baltimore
  • New Hope Treatment Center - Baltimore
  • Day Break Methadone Clinic - Baltimore

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2006-04
Est. Completion 2011-05
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT00279110

The ClinicalTrials.gov registry entry for NCT00279110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Directly administered antiretroviral therapy (DAART) is the first listed.

NCT00279110 reports 5 study locations spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00279110 about?

NCT00279110 is a clinical study titled "Directly Administered HIV Therapy in Methadone Clinics". The purpose of this study is to determine whether providing directly administered antiretroviral therapy to HIV-infected who receive methadone therapy leads to better treatment outcomes than if they take HIV medications on their own.

What is the current status of trial NCT00279110?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2006-04. Estimated completion is 2011-05.

What conditions does trial NCT00279110 study?

This clinical trial studies the following conditions: HIV Infections, Heroin Dependence.

What interventions are being tested in trial NCT00279110?

The interventions under investigation include: Directly administered antiretroviral therapy (DAART) (BEHAVIORAL).

Who is sponsoring clinical trial NCT00279110?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00279110 being conducted?

This trial has 5 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.